A New Medicine to Prevent Opioid Dependence
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
This project aims to create a new non-opioid medicine to help prevent people from becoming dependent on opioids after receiving them in the hospital.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vivreon Biosciences, LLC NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project ID | NIH-11135560 on NIH RePORTER |
What this research studies
Many patients in the hospital, especially those in trauma or intensive care, receive opioids for pain and sedation. Repeated use can lead to dependence, strong cravings, and withdrawal symptoms, putting them at risk for opioid use disorder after discharge. This often extends hospital stays and increases healthcare costs. Our goal is to develop a new type of medicine that is not an opioid, which could prevent this dependence from happening. This new medicine would help patients avoid the cycle of dependence and reduce their risk of developing opioid use disorder.
Who could benefit from this research
Good fit: Ideal candidates for future studies would be hospitalized patients who are receiving opioids for pain management, particularly those in trauma or intensive care units.
Not a fit: Patients who are not currently receiving opioids or who have already developed established opioid use disorder may not directly benefit from this specific preventative approach.
Why it matters
Potential benefit: If successful, this new medicine could significantly reduce the risk of opioid dependence and opioid use disorder for hospitalized patients, leading to better health outcomes and shorter hospital stays.
How similar studies have performed: This project focuses on developing a novel, non-opioid chemical entity, representing a new and untested approach to preventing opioid dependence.
Where this research is happening
San Diego, UNITED STATES
- Vivreon Biosciences, LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Greenberg, Milton L — Vivreon Biosciences, LLC
- Study coordinator: Greenberg, Milton L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.